Jyoti Mayadev, MD, professor, assistant vice chair, Developmental Therapeutics, section chief, Gynecologic Oncology, co-leader, GYN Oncology Disease Team, Moores NCI-Designated Comprehensive Cancer Center, UC San Diego School of Medicine, discusses the phase 1 NRG-GY017 trial (NCT03738228) evaluating atezolizumab (Tecentriq) given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

The key takeaway from the trial is that it was safe to combine an anti–PD-L1 agent with chemoradiation, Mayadev says. Few dose-limiting toxicities were observed with this approach in this population, Mayadev adds. Additionally, when examining T-cell clones in the patient's peripheral blood and the tumors, it was found that patients who received chemoradiation had an expansion of T-cell clonality. Notably, new, novel clones were observed, as opposed to tumor-associated clones, Mayadev concludes.

Videos

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.


Jyoti Mayadev, MD

Articles

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer